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Abstract
The Endosomal Sorting Complexes Required for Transport (ESCRT) machinery, a highly conserved set of four hetero-
oligomeric protein complexes, is required for multivesicular body formation, sorting ubiquitinylated membrane proteins for
lysosomal degradation, cytokinesis and the final stages of assembly of a number of enveloped viruses, including the human
immunodeficiency viruses. Here, we show an additional role for the ESCRT machinery in HIV-1 release. BST-2/tetherin is a
restriction factor that impedes HIV release by tethering mature virus particles to the plasma membrane. We found that HRS,
a key component of the ESCRT-0 complex, promotes efficient release of HIV-1 and that siRNA-mediated HRS depletion
induces a BST-2/tetherin phenotype. This activity is related to the ability of the HIV-1 Vpu protein to down-regulate BST-2/
tetherin. We found that BST-2/tetherin undergoes constitutive ESCRT-dependent sorting for lysosomal degradation and that
this degradation is enhanced by Vpu expression. We demonstrate that Vpu-mediated BST-2/tetherin down-modulation and
degradation require HRS (ESCRT-0) function and that knock down of HRS increases cellular levels of BST-2/tetherin and
restricts virus release. Furthermore, HRS co-precipitates with Vpu and BST-2. Our results provide further insight into the
mechanism by which Vpu counteracts BST-2/tetherin and promotes HIV-1 dissemination, and they highlight an additional
role for the ESCRT machinery in virus release.
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Introduction
The assembly and release of HIV-1 particles requires a highly
orchestrated series of interactions between proteins encoded by the
virus and key cellular components, including elements of the
cellular membrane trafficking apparatus and the ESCRT
(Endosomal Sorting Complexes Required for Transport) machin-
ery [1,2,3]. The ESCRT machinery was initially found to be
involved in the recognition and sorting of membrane proteins to
the internal vesicles of multivesicular bodies (MVBs)/late endo-
somes and the subsequent degradation of these cargoes in
lysosomes. Subsequently, the ESCRT machinery was found to
also play key roles in topologically related membrane scission
reactions that occur during cytokinesis and the budding of a
number of enveloped viruses, including HIV-1 [1,4]. The ESCRT
machinery comprises four multiprotein complexes ESCRT-0, -I,
-II and -III whose sequential recruitment to endosomal mem-
branes mediates (1) the formation (budding) and subsequent
pinching off of intralumenal endosomal vesicles into MVBs and (2)
the incorporation of ubiquitinylated membrane protein cargoes
into the inwardly budding vesicles [4]. The ESCRT-0 protein
HRS (also called hepatocyte growth factor-regulated tyrosine
kinase substrate [HGS]) initiates this process by acting as a linker
protein that binds, on the one hand, ubiquitinylated cargoes and,
on the other, a PSAP motif in the ESCRT-I component TSG101
[4].
Topologically, the budding of HIV-1 particles at the plasma
membrane resembles the budding of intralumenal vesicles into
MVBs. Moreover, the HIV-1 Gag protein, the major structural
protein of the virus, can recruit the ESCRT-I and ESCRT-III
complexes through its C-terminal p6 domain (so called ‘‘late
domain’’) to mediate release of budding virions [5,6,7,8]. A PTAP
motif in the Gag p6 domain binds TSG101, mimicking the HRS-
PSAP mediated recruitment of ESCRT-I. Failure to recruit
ESCRT-I, and consequently ESCRT-III, leads to accumulation of
viral budding intermediates at the surface of infected cells [5,8]. In
addition, a LYPXnL motif in the Gag p6 domain provides a
second means to recruit the ESCRT machinery by binding the
ESCRT-I and ESCRT-III interacting protein ALIX/AIP1 [7].
Although Gag mimics HRS in binding TSG101, HRS itself is not
required for the HIV-1 budding and scission reactions [9].
Nevertheless, HRS was recently identified in a genome-wide
siRNA screen for host cell factors involved in HIV-1 replication,
suggesting an active role for ESCRT-0 [10].
In this study, we explored the role of HRS in the HIV-1
replication cycle. Using RNA interference and virological assays,
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particles. HRS function was not related to the described TSG101
activity in HIV-1 scission, but was related to the ability of the
accessory viral protein Vpu to down-regulate the protein bone
marrow stromal antigen 2 (BST-2 also called CD317/HM1.24/
tetherin). BST-2 was recently identified as a cellular restriction
factor that impedes the release of fully assembled HIV-1 by
physically tethering particles to the plasma membrane of infected
cells. Vpu counteracts this restriction and induces the down-
regulation of BST-2 expressed at the cell surface. Vpu-induced cell
surface down-regulation of BST-2 is associated with targeting of
the cellular protein for degradation [11,12,13,14,15]. Here we
show that BST-2 undergoes constitutive ESCRT-mediated
lysosomal degradation. Moreover, HRS facilitates Vpu-induced
BST-2 down-regulation and degradation, and therefore contrib-
utes to efficient HIV-1 release. Furthermore HRS co-precipitates
with Vpu and BST-2. Altogether, our results highlight an
additional role for the ESCRT machinery in HIV-1 release, and
provide further understanding of the mechanism by which Vpu
targets BST-2 for degradation.
Results
HRS is required for efficient HIV-1 release
To investigate the role of the ESCRT-0 component HRS on
HIV-1 replication, we specifically depleted HRS in HeLa cells and
analysed the effect on HIV-1 propagation. We used a siRNA
against HRS that has been described and validated in earlier
studies ([16] Cf. Experimental procedures). By western-blot
analysis, siRNA transfections into HeLa cells resulted in .95%
reduction in HRS levels, as previously described ([16]; Figures 1A
and C). We assessed the impact of HRS silencing on the ability of
the NL4-3 strain of HIV-1 (NL4-3 WT) to propagate in the
reporter cell line HeLa P4R5 (stably expressing the receptor CD4
and the coreceptor CCR5). The cells were either treated with a
control siRNA (siRNA CT; referred to as control cells) or with
siRNA targeting HRS (siRNA HRS), then infected with NL4-3
HIV-1 at a MOI of 0.005 and left for 4 days to allow the virus to
propagate through the cultures. HIV-1 production was scored by
ELISA quantification of the Gag product CAp24, reflecting the
amount of virus present in the supernatant. Figure 1B shows that
depletion of HRS caused a significant reduction in virus release,
with ,10% CAp24 detected in the supernatant of these cells
compared to the control cells, suggesting that HRS is required for
optimal HIV-1 replication.
As HIV-1 entry into HRS-depleted cells was not affected
(Figure S1), we tested whether the reduction in HIV-1 propagation
observed following HRS knock down was a consequence of
decreased production of viral particles. To this end, HeLa cells
were transfected with control siRNA (siRNA CT) or siRNA
targeting HRS (siRNA HRS), and then infected with NL4-3 HIV-
1 pseudotyped with VSV-G (NL4-3 WT) at an MOI=0.5. VSV-
G pseudotyping enables HIV-1 production to be monitored after a
single round of infection. Forty-eight hours after infection the
protein content of the cells was analyzed by western-blot
(Figure 1C) and the virus released into the supernatant was
assessed by western-blot and ELISA quantification of CAp24
(Figures 1D–E). Depletion of HRS (Figure 1C) did not significantly
modify the maturation of Gag compared to the control cells.
However, in HRS-depleted cells a clear accumulation of Env
(gp160, SUgp120 and TMgp41) and of the processed Gag
products, CAp24 and MAp17, was observed (Figures 1C–E).
The expression levels of the viral accessory proteins Nef and Vpu
were similar in both CT and HRS knock down cells. As these
accessory proteins are not incorporated significantly into nascent
viral particles, we postulated that the increased level of cell-
associated Env and processed Gag products, CAp24 and MAp17,
might be due to a decrease in HIV-1 release from HRS depleted
cells. Quantification of the amount of CAp24 in the cell
supernatants (Figures 1D and 1E) and western-blot analysis of
viral preparations (Figure 1C, lower panel) confirmed that virus
release was decreased by 60–70% in HRS knock down cells. These
data indicate that HRS is required for efficient HIV-1 release from
HeLa cells.
HRS does not interfere with the Gag-related function of
TSG101 in HIV-1 morphogenesis
To understand the mechanism by which HRS contributes to
HIV-1 release, we assessed whether HRS depletion perturbed Gag
recruitment of TSG101. To this end, we analysed the ability of a
GST-p6 fusion construct, corresponding to the sub-domain of Gag
bearing the PTAP motif involved in TSG101 interaction, to
interact with TSG101 in control and HRS depleted cells.
Figure 2A shows similar levels of binding of GST-p6 to TSG101
in control and HRS depleted cells (Figure 2A, compare lane 7 with
lane 8). Similar results were obtained using a GST-Gag construct
(Figure S2) suggesting that HRS is not required for p6-mediated
binding of Gag to TSG101 and recruitment of ESCRT-I.
We then analyzed whether depletion of HRS and TSG101 led
to similar alteration of virus production using the assay described
above. As shown in Figure 2C, both HRS and TSG101 depletion
reduced HIV-1 release from infected cells, as assessed by
quantitative ELISA. However, western-blot analysis of cell-
associated viral proteins suggested that HRS and TSG101 have
different roles in HIV-1 production (Figure 2B). Depletion of
TSG101, as well as expression of viruses mutated in the Gag
PTAP motif, induced a profound alteration in Gag processing,
characterized by an accumulation of the p41 and CA-SP1 Gag
processing intermediates as previously described [5,6]. No such
alteration was observed upon depletion of HRS (Figures 1C and
2B). Infectious viral release from the siRNA-transfected cells was
then scored using the indicator cell line HeLa TZM-bl, and the
results were normalized to the amount of CAp24 present in the
cell supernatants. As previously shown, particles produced by
TSG101 depleted cells were mostly non-infectious due to defects
Author Summary
The release of HIV-1 particles requires a series of
interactions between proteins encoded by the virus and
key cellular components, including elements of the cellular
membrane trafficking apparatus such as the Endosomal
Sorting Complexes Required for Transport (ESCRT) ma-
chinery. This machinery is composed of four multiprotein
complexes (ESCRT-0, -I, -II and –III) that are involved in the
sorting of ubiquitinylated membrane proteins for lyso-
somal degradation. Gag, the major structural protein of
HIV, recruits the ESCRT-I and III complexes to mediate the
scission of budding virions. Following ESCRT-mediated
scission of viral particles, the HIV-1 accessory protein Vpu
promotes the release of the mature virions by counter-
acting a cellular restriction factor BST-2/tetherin that
physically tethers viral particles to the plasma membrane
of infected cells. Here we show that HRS, a component of
the ESCRT-0 complex, is required for Vpu to efficiently
modulate the expression of BST-2 and promote HIV-1
release, highlighting an additional role of the ESCRT
machinery in virus production.
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PLoS Pathogens | www.plospathogens.org 2 February 2011 | Volume 7 | Issue 2 | e1001265Figure 1. Depletion of HRS reduces the release of HIV-1 particles from infected cells. (A–B) HRS depletion impairs HIV-1
propagation. HeLa P4R5 MAGI cells transfected with either siRNA control (siRNA CT) or siRNA targeting HRS (siRNA HRS) were non-infected (NI) or
infected with NL4-3 HIV-1 WT at a low MOI=0.005 and left for 4 days to allow viral propagation. (A) Western-blot analysis of infected siRNA treated
cells. Tubulin is the loading control. (B) HIV-1 propagation was scored by ELISA quantification of extracellular CAp24 present in the culture
supernatants. (C–E) HRS depletion reduces HIV-1 release. HeLa cells transfected with either control siRNA (CT) or siRNA targeting HRS were
infected with VSV-G-pseudotyped HIV-1 (NL4-3 WT). (C) Western-blot analysis of infected siRNA-treated cells (upper panels) and pelleted viruses
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PLoS Pathogens | www.plospathogens.org 3 February 2011 | Volume 7 | Issue 2 | e1001265(lower panel). Tubulin is the loading control. (D) CAp24 present within the cells (Cell-associated CAp24, dark-grey graph bars) and released from the
infected cells (Released CAp24, light-grey graph bars) was measured by ELISA. The experiment was performed in duplicate. Bars represent the mean
-/+ SD from each duplicate. (E) For HRS depleted cells, amounts of released and cell-associated CAp24 obtained by ELISA in (D) were normalized to
those obtained for the corresponding control cells (set as 100%). Bars represent the mean 2/+ SD from 4 independent experiments.
doi:10.1371/journal.ppat.1001265.g001
Figure 2. HRS depletion does not interfere with TSG101-mediated budding of HIV-1. (A) Binding of TSG101 to the p6 domain of
Gag. Lysates of HeLa cells transfected with either control siRNA (CT) or siRNA targeting HRS or TSG101 were incubated with equal amounts of
purified GST (lanes 4 to 6) or GST-p6 (lanes 7 to 9). TSG101 binding and HRS depletion were analysed by western blotting (upper panels). Tubulin is
the loading control for cellular proteins. Lower panel: Ponceau red staining of the membrane used for western blotting. These data are representative
of 2 independent experiments. (B–D) Impact of HRS and TSG101 depletion on HIV-1 assembly. HeLa cells transfected with either control
siRNA (CT) or siRNA targeting HRS or TSG101 were infected with VSV-G-pseudotyped NL4-3 HIV-1 (NL4-3 WT). (B) Western-blot analysis of infected
siRNA-treated cells. Tubulin is the loading control. Asterisk (*) shows the CA-SP1 Gag processing intermediate. (C) HIV-1 CAp24 present within the
cells (Cell-associated CAp24, dark-grey graph bars) and released in the supernatant of the infected cells (Released CAp24, light-grey graph bars) was
measured by ELISA. Values obtained for HRS or TSG101 depleted cells were normalized to those of the control cells set to 100%. Bars represent the
mean 2/+ SD from 3 independent experiments. (D) The virus titre was scored by infection of HeLa TZM-bl indicator cells, followed by luciferase
activity quantification in the cells. The values obtained were normalized to the amount of released CAp24 quantified in (C). Bars represent the mean
2/+ SD from 4 independent experiments.
doi:10.1371/journal.ppat.1001265.g002
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released from control cells) [5]. By contrast, the virions produced
from HRS depleted cells exhibited ,45% loss of infectivity
compared to control viruses (Figure 2D). Interestingly, western-
blot analysis of viral particles showed a decrease in envelope
glycoprotein (Env) incorporation (Figure S3), which may explain
this lower infectivity. HRS might also be required for the proper
intracellular trafficking and processing of Env within infected cells.
Therefore, HRS depletion might result in intracellular accumu-
lation and incorporation of mature and unprocessed Env products
unfit for HIV-1 infectivity (Figures 1C, 2B, 2D). Taken together,
our data indicate that HRS is required for efficient HIV-1 release
from HeLa cells, and its mode of action is distinct from that of
TSG101 in HIV-1 budding.
HRS depletion leads to accumulation of HIV-1 particles at
the cell surface and in endosomes
To further explore the mechanism by which HRS reduces
HIV-1 release, siRNA treated HeLa cells infected with VSV-G
pseudotyped NL4-3 HIV-1 were prepared for cryosectioning and
electron microscopy (EM). Initially, immunofluorescence staining
of semi-thin survey cryosections with antibodies against the viral
proteins MAp17 and Env revealed a large number of HIV-
infected cells (Figure 3A and 3B). The anti-MAp17 antibody 4C9,
which detects only the cleaved Gag product MA, labelled small
spots probably representing mature virions, as well as larger
clumps of viruses, confirming that HRS depletion does not inhibit
Gag processing and maturation of HIV-1 particles. Staining with
antibodies against Env was observed over the endoplasmic
reticulum, with juxta-nuclear patches of brighter staining, and
some Env labelling co-localized with p17 stained viruses. On
sections from HRS knockdown cells, the staining for p17 and Env
was much stronger than on the control cells, with large clumps of
viruses observed near the cell surface, sometimes attached via fine
processes. Some virus was also observed in cytoplasmic vacuoles
(Figure 3B).
To analyse the accumulations of virus particles in more detail,
we stained ultrathin cryosections (50 nm) for p24/p55Gag and
Env with protein A-gold (PAG) for EM. For both the control and
HRS siRNA-treated samples, infected cells could be identified by
scattered p55Gag labelling (5 nm PAG) over the cytoplasm, but
not over nuclei, demonstrating specificity of the labelling
(Figures 3C–E and 3H). Env was seen over the Golgi apparatus
and associated small tubulo-vesicular membranes (Figure S4A and
S4C). Virus particles were labelled with antibodies against both
p24/p55Gag (5 nm PAG) and Env (10 nm PAG), showing that
Env-containing virions were produced by control and HRS-
depleted cells. On control cells, the virus particles were seen either
singly or in small clusters at the cell surface (Figure 3C and 3D),
and occasionally virus particles could also be observed in
intracellular vacuoles (Figure 3E). On the HRS-depleted cells,
much larger clusters of HIV particles were attached to the cell
surface either directly or via microvillar protrusions (Figure 3F, the
upper of these virus clusters is enlarged in Figure 3G). Some of
these clusters contained .20 and sometimes as many as 80–100
virus particles. In addition, we observed intracellular vacuoles
resembling endosomes containing many p24/p55Gag and Env-
immunolabelled virus particles in some of the HRS-depleted cells
(Figure 3H, 3I and S4F).
We confirmed these observations by counting the distribution of
669 and 395 virus particles in the HRS-depleted and control cells,
respectively. On the HRS-depleted cells, 47% of the virus particles
were in clusters of more than 20 particles, while in control cells
about half of the viruses occurred alone or in groups of 2–4
particles, and no virus clusters contained more than 18 virions. In
addition, for the HRS-depleted cells, 27% of the virus particles
were seen in intracellular vesicles, while for the control cells only
7% of virus particles were in endosomes. The large extracellular
virus clusters and accumulation of virus particles in endosomes in
the HRS-depleted cells was reminiscent of the phenotype observed
in BST-2/tetherin-expressing cells infected with Vpu-defective
HIV-1 strains [13,15]. This suggests that depletion of HRS in
HeLa cells leads to tethering of viral particles at the cell surface
and their subsequent endocytosis, and that HRS knock down may
affect the trafficking of BST-2.
The ESCRT machinery targets BST-2 for degradation
The HIV-1 accessory protein Vpu counteracts the cellular
restriction factor BST-2 to promote HIV-1 release. BST-2
physically tethers newly formed viral particles at the surface of
infected cells, preventing their release. Vpu relieves this restriction
by down regulating cell surface expression of BST-2. In addition,
Vpu promotes the degradation of BST-2 [11,12,13,14,15,17].
Based on the EM observations above, we postulated that HRS
might contribute to the process of Vpu inhibition of BST-2
restriction. As the ESCRT machinery sorts ubiquitinylated
membrane proteins for lysosomal degradation, we analysed
whether HRS, and by extension the MVB pathway, participates
in the degradation of BST-2. HeLa cells were transfected with
siRNAs targeting HRS or TSG101 and the turnover of BST-2 was
monitored after incubating the cells in growth medium containing
cycloheximide. We observed that almost 90% of BST-2 was
degraded in 4 hours in cells transfected with control siRNA
(Figure 4A; siRNA CT). By contrast, in HRS depleted cells, the
half-life of BST-2 was prolonged, with only 30% of the initial BST-
2 pool degraded after 4 hours (Figure 4A; siRNA HRS). Western-
blot and immunofluorescence analysis revealed increased BST-2
expression in HRS depleted cells compared to the control cells,
consistent with stabilization of the protein (Figure S5A and C). We
also investigated the role of TSG101 in the degradation of BST-2.
As TSG101 depletion is achieved more rapidly than HRS
depletion (,2 days and 4 days, respectively), the cells were
harvested 72 hours after siRNA transfection (Figure 4B). As
observed with HRS knock down, loss of TSG101 also stabilized
BST-2 expression (less than 10% degradation in 4 hrs; Figure 4B).
This stabilization was also associated with a striking accumulation
of BST-2 within intracellular structures that partially co-labelled
for HRS (Figure S5B and C). As an internal control, we monitored
the turnover of EGF receptors (EGF-R) following EGF stimula-
tion. Upon ligand binding, EGF-R is targeted to MVBs prior to
lysosomal degradation [18,19]. Consistent with these previous
studies, knock down of HRS (Figure 4A) or TSG101 (Figure 4B)
inhibited EGF-induced EGF-R degradation compared to control
cells (Figures 4A–B, lower panels). These data show that HRS and
TSG101 are involved in the sorting of BST-2 for degradation in
the MVB/lysosomal pathway.
To obtain further evidence for the involvement of the ESCRT
machinery in BST-2 trafficking, we analysed the effect of over-
expressing HRS,orexpressinga dominantnegativemutantofthe v-
ATPase VPS4 (VPS4-E223/Q), on BST-2 expression. Over-
expression of HRS was shown to negatively perturb the ESCRT
pathway [18]. VPS4 is an AAA-ATPase involved in recycling the
ESCRT machinery by facilitating its dissociation from endosomal
membranes [20].Mutationof E223 to Q blocks ATPhydrolysisand
renders VPS4-E223/Q a dominant-negative inhibitor of the
ESCRT pathway [20]. Immunofluorescence microscopy showed
that in cells expressing GFP-HRS, BST-2 accumulated within
enlarged endosomal structures that co-labelled with GFP-HRS,
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PLoS Pathogens | www.plospathogens.org 5 February 2011 | Volume 7 | Issue 2 | e1001265Figure 3. Silencing of HRS leads to accumulation of HIV-1 particles in at the cell surface and in endosomes. HeLa cells transfected with
either siRNA control (A and C–E) or siRNA targeting HRS (B and F–I) were infected with VSV-G-pseudotyped HIV-1 for 48 hrs, fixed and prepared for
cryosectioning. (A, B) Immunofluorescence analysis of MAp17 and Env distribution on semi-thin cryosections. Semi-thin (0.5 mm)
cryosections were immunostained with mouse anti-MAp17 and anti-mouse-Alexa-488 (green) and 2G12 anti-HIV-Env and anti-human- Alexa-594
(red). MAp17 staining reveals fine spots probably representing virus particles at the surface of the cells, as well as larger clumps of virus staining
(arrows) which can correspond to phase-dark structures at the surface of the cell profiles in the phase images shown in the right hand panels. Many
more clumps of MAp17 staining were observed on the HRS-depleted cells (B). In addition, some virus staining was seen in intracellular vacuoles
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discrete punctuate structures (Figure 4C, panels d-f). Similarly,
expression of the VPS4 dominant negative mutant resulted in a
striking accumulation of BST-2 (Figure 4C, panels j-l), suggesting
that expression of VPS4-E223/Q as well as over-expression of HRS
inhibited BST-2 degradation compared to control cells expressing
wild type VPS4 or GFP alone (Figure 4C). Together, our results
indicate that BST-2is rapidlyturned over inHeLacellsand that the
ESCRT machinery is required for its efficient degradation.
Impact of HRS depletion on the release of Vpu-defective
HIV-1
As Vpu expression promotes the release of virus particles from
restrictive BST-2-positive cells [13,15], we analysed the effect of
HRS depletion on the production of Vpu-defective HIV-1. To this
end, HeLa cells were transfected with control siRNA or siRNA
targeting HRS and then infected with either VSV-G pseudotyped
wt NL4-3 HIV-1 (NL4-3 WT) or VSV-G pseudotyped Vpu-
defective NL4-3 HIV-1 (NL4-3 Udel) at an equivalent MOI
(MOI=0.5). The cell proteins were then analysed by western-blot
and the viral particles released into the cell supernatants measured
by CAp24 ELISA and analysed by western-blot. As previously
described [13,15], the release of Vpu-defective HIV-1 particles
from restrictive cells was poor compared to wild type virus
(Figure 5). Interestingly, in HRS knock down cells, the release of
Vpu-deleted HIV-1 was also lower (,40% less virus) compared to
the control cells (Figure 5A, lower panel and Figure 5B). As
observed for WT viruses, the reduced release of Vpu-defective
HIV-1 observed in HRS depleted cells was associated with
increased amounts of cell-associated Gag/CAp24 (Figure 5B).
These results suggest cooperation between Vpu and HRS to
promote efficient HIV-1 release.
Impact of HRS depletion on HIV-1 release from cells
lacking BST-2
Cells such as PBMC, HEK 293T, COS, HT1080, and HOS do
not normally express BST-2. These cells are referred to as ‘non-
restrictive’and releasetheVpu-defectiveHIV-1asefficiently aswild
type viruses [13,15,21]. To further explore the role of HRS in the
BST-2 restriction of HIV-1 release, we compared the effect of HRS
depletion on HIV-1 production in non-restrictive HEK 293T cells
and restrictive HeLa cells (Figure 6). RNAi mediated HRS knock
down was similar in HEK 293T and HeLa cells (.95%; Figure 6).
In HeLa cells (Figure 6A and 6B), HRS depletion inhibited the
release of HIV-1 and induced an accumulation of cell-associated
CAp24 as shown before. In the HEK 293T cells, a reduced amount
ofCAp24wasdetected inthe supernatant,butthiswasparalleled by
a decrease in the amount of cell-associated CAp24 (Figure 6A and
6C) compared to the control. Thus, in HEK 293T cells the
decreased p24 release most likely reflects reduced HIV-1 infection
rather than a defect in virus release (Figure 6C).
To circumvent the caveats caused by the lower sensitivity of
HRS depleted HEK 293T cells to HIV-1 infection, we analysed
the outcome of HRS depletion in HeLa cells depleted for BST-2
(Figure 7). HeLa cells were transfected with CT siRNA or siRNA
targeting HRS and BST-2 alone or together and then infected
with either VSV-G pseudotyped wt NL4-3 HIV-1 (NL4-3 WT) or
VSV-G pseudotyped Vpu-defective NL4-3 HIV-1 (NL4-3 Udel) at
an equivalent MOI (MOI=0.5). As previously described, the
release of Vpu-defective HIV-1 was rescued in cells depleted for
BST-2 compared to the control cells (Figure 7A lower panel;
compare lane 7 to lane 5, see Figure 7B), consistent with a
restriction of Vpu-defective virus release by BST-2 [13,15].
Interestingly HRS depletion did not affect the release of NL4-3
wt viral particles in BST-2 depleted cells (lower panel, compare
lane 4 to lane 2; Figure 7B), as similar amounts of virus were
produced from these cells compared to the control cells (compare
lane 4 to lane 1). Similarly, release of NL4-3 Udel viruses was no
longer affected by HRS depletion in HeLa cells devoid of BST-2
(Figure 7, lower panel, compare lane 8 to lane 6, see Figure 7B).
These results support the notion that HRS does not play a major
role in HIV-1 release from non-restrictive cells and suggest that
HRS may contribute to the activity of Vpu in counteracting BST-
2/tetherin mediated restriction of virus release.
HRS is required for the Vpu-induced down regulation of
BST-2
We observed that HRS is involved in the constitutive
degradation of BST-2 (Figure 4A) and appears to promote HIV-
1 release from restrictive cells (Figures 1C–E). We therefore tested
whether HRS is required for Vpu induced BST-2 degradation.
RNAi-treated HeLa cells were infected with either VSV-G
pseudotyped wt NL4-3 (NL4-3 WT) or Vpu-deleted NL4-3
(NL4-3 Udel) viruses at a MOI of 1 to infect the majority of the
cells. Forty-eight hours after infection, the cells were incubated in
medium containing cycloheximide to monitor the degradation of
BST-2 with time (Figure 8A). As described above (Figure 4), the
level of BST-2 decreased in control cells in 4 hours of treatment
with cycloheximide. By contrast, BST-2 levels were stabilized in
HRS depleted cells over 4 hours (Figure 8A, compare lanes 1–2
with lanes 3–4). A similar pattern was observed in cells infected
with Vpu-defective viruses (lanes 9–10 to 11–12). In control cells
infected with NL4-3 WT, BST-2 was barely detectable at time 0,
consistent with Vpu-enhanced degradation of BST-2 (lanes 5–6).
Interestingly, in HRS depleted cells, BST-2 levels were similar to
those in uninfected cells or cells infected with Vpu-defective viruses
at time 0 and remained stable during 4 h of treatment with
cycloheximide (Figure 8A, lanes 7–8). Immunofluorescence
staining showed that, in control cells, HIV-1 infection (revealed
by staining for Env) led to reduced BST-2 staining, compared to
neighbouring non-infected cells, whereas BST-2 labelling was
comparable in infected and non-infected cells when HRS was
depleted (Figure 8B). These data show that HRS depletion
impedes the ability of Vpu to target BST-2 for degradation. Taken
together, our data indicate that Vpu-induced BST-2 degradation
involves the ESCRT/MVB pathway.
Although Vpu expression can induce BST-2 degradation, the
mechanism by which Vpu inhibits BST-2 restriction of HIV-1
release is unclear. Treatment of cells with the v-ATPase inhibitor
bafilomycin A1, which inhibits both endosomal sorting and
(arrowheads). Scale bars =10 mm. (C–I) ImmunoEM analysis of Gag and Env distribution. Ultrathin cryosections (50 nm) were labelled with
anti-Gag p24/p55 (5 nm PAG) and anti-Env 2G12 (10 nm PAG). Infected cells show scattered 5 nm gold particles over the cytoplasm (thin arrows), but
not over the nucleus (Nu). In the control cells immature and mature virus particles could be seen at the cell surface, individually or in small groups (C)
or in small clumps (D) and, occasionally, in intracellular vacuoles (E). In cells treated with HRS siRNA, much larger clusters of HIV particles were seen at
the cell surface or attached to microvillus-like cell surface protrusions (Mv) (F, the upper virus cluster is enlarged in G). In addition, intracellular
vacuoles or endosomes (En) containing many virus particles were frequently seen (H, I). The thick arrow in F identifies a budding virus, and the
arrowheads in H and I mark small intralumenal vesicles in the virus-containing endosomes. Scale bars in C–E and G–I =200 nm, F=500 nm.
doi:10.1371/journal.ppat.1001265.g003
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PLoS Pathogens | www.plospathogens.org 8 February 2011 | Volume 7 | Issue 2 | e1001265lysosomal function, can restore BST-2 cell surface levels in cells
expressing Vpu, most likely due to the recycling of BST-2 [17]. We
thus wondered whether depleting HRS counteracts Vpu-mediated
down regulation of cell surface BST-2. To answer this question,
siRNA transfected HeLa cells were infected with VSV-G
pseudotyped wt NL4-3 HIV-1 (NL4-3 WT) at a MOI of 0.5 so
that approximately50% ofthecellswereinfected.Cell surfacelevels
of BST-2 were assessed by flowcytometry(Figures 8C–D and Table
S1). Intracellular staining of CAp24 (CAp24-FITC) was used to
distinguish non-infected cells (Figure 8C–D: gate B1 and black bars)
from infected cells (Figure 8C–D: gate B2 and grey bars). In control
cells (siRNA CT) infected with WT NL4-3 HIV-1, BST-2 cell
surfaceexpression decreased by$60%compared with non-infected
cells, consistent with previous studies [15,22]. Interestingly, the
Vpu-induced down regulation of cell surface BST-2 was impaired
upon depletion of HRS since no significant decrease of cell surface
BST-2 was observed on infected HRS depleted cells (less than 20%
decrease) compared to non-infected HRS depleted cells (Figure 8C–
D and Table S1). Our data suggest that disruption of BST-2 sorting
in endosomes by HRS depletion diminishes the ability of Vpu to
down-regulate cell surface BST-2, most likely by allowing
internalized BST-2 to recycle to the cell surface.
The v-ATPase VPS4 is required for Vpu-induced cell
surface down regulation of BST-2
To obtain further evidence that the mechanism by which Vpu
counteracts BST-2 involves the ESCRT machinery, we analysed
the effect of over-expressing a dominant negative mutant of the
AAA-ATPase VPS4 (VPS4-E223/Q) on Vpu-induced down-
regulation of cell surface BST-2. HeLa cells were co-transfected
with plasmids encoding wt VPS4 or VPS4-E223/Q fused to GFP
along with the plasmid encoding the provirus wt NL4-3 HIV-1
(NL4-3 wt) or Vpu-defective NL4-3 HIV-1 (NL4-3 Udel) as a
control. Cell surface levels of BST-2 were assessed by flow
cytometry on GFP positive infected cells (surface staining of Env
was used to identify HIV-1 expressing cells) (Figure 9). In cells
expressing wt VPS4, a marked decrease of cell surface BST-2 was
observed in cells expressing HIV-1 NL4-3 wt compared to cells
expressing Vpu-defective viruses (Figure 9A, upper left panel and
Figure 9B), consistent with Vpu-induced down–regulation of cell
surface BST-2 [11,12,15,17,22]. Interestingly, expression of VPS4-
E223/Q impaired the ability of Vpu to down-regulate BST-2 from
the cell surface, as similar levels of BST-2 were detected at the
surface of cells expressing WT and Vpu-defective viruses (Figure 9,
upper right panel and Figure 9B). Together with the results
obtained from depleting HRS (Figure 8C–D), our data suggest
that the integrity of the ESCRT machinery is required for Vpu to
down-regulate BST-2 from the cell surface.
HRS interacts with BST-2 and Vpu
We showed that HRS is required for the targeting of BST-2 to
the degradation pathway (Figure 4) and for the ability of Vpu to
down-regulate BST-2 (Figures 5 and 8) to promote efficient release
of HIV-1 particles. Since HRS is physiologically involved in the
recognition of cargo on endosomal membranes, we postulated that
HRS might interact with BST-2 and/or Vpu. To test this, HEK
293T cells were transfected with plasmids encoding HRS fused to
SBP-CBP tags (SBP-CBP-HRS) along with Flag-BST-2 and/or
HA-Vpu. Interaction with HRS was assessed by pull-down of
SBP-CBP-HRS followed by western-blot analyses of bound
proteins. Figure 10 shows that HRS interacts with Flag-BST-2
(Figure 10, Lane 6) and is also able to bind HA-Vpu (Figure 10,
Lane 7). Interestingly all three proteins co-precipitated when
expressed together (Figure 10, Lane 8), and HRS apparently
bound more BST-2 in the presence of Vpu. This suggests that Vpu
enhances the recognition of BST-2 by the ESCRT machinery,
perhaps by bridging BST-2 and HRS.
Discussion
Studies of the mechanism through which HIV-1 particles are
assembled and released from infected cells have revealed a major
role for the ESCRT machinery. ESCRT-I and ESCRT-III
complexes are recruited to sites of virus assembly by binding to
the viral Gag protein, promoting the scission of assembled viral
particles [5,6,7,8]. An additional step in the release of mature virus
has been highlighted through studies of the HIV-1 accessory
protein Vpu. Vpu had been implicated in the efficient release of
HIV-1 from certain cell lines (referred to as restrictive cells) but its
cellular target was unknown. Recently, BST-2/tetherin was
identified as a cellular restriction factor that impedes the release
of HIV-1 by physically tethering fully formed mature particles to
the plasma membrane of infected cells. It was proposed that, by
reducing BST-2/tetherin cell surface expression, Vpu abrogates
BST-2/tetherin function, thus allowing efficient virus release
[12,13,14,15,17,22]. Here we show that the HRS component of
the ESCRT-0 complex facilitates Vpu-induced BST-2 down-
regulation and degradation, thereby contributing to efficient HIV-
1 release. Our data thus highlight an additional role for the
ESCRT machinery in HIV-1 release, following ESCRT-mediated
membrane scission.
Physiologically, HRS is thought to initiate the ESCRT-
mediated formation of MVBs. A PSAP motif in HRS recruits
the ESCRT machinery to endosomal membranes through
interaction with the ESCRT-I component TSG101 [16]. These
events are mimicked by HIV when ESCRT-I is recruited to
budding sites through a similar PTAP motif in the C-terminal p6
‘‘late domain’’ of Gag [6,9]. Although HRS is not needed to
recruit the ESCRT machinery for viral scission [9], we show that it
is required to promote efficient Vpu-dependent release of HIV-1
particles following completion of the budding reactions. The
reduced HIV-1 release caused by HRS depletion is not a
consequence of an indirect effect on the ability of Gag to recruit
TSG101, as HRS depletion neither impaired the binding of Gag
to TSG101 nor altered Gag processing (Figure 2; [5]). A role for
Figure 4. The ESCRT machinery sorts BST-2 for degradation. (A) Analysis of BST-2 turnover following HRS depletion. HeLa cells were
transfected with either control siRNA (CT) or siRNA targeting HRS. Four days later the cells were incubated with cycloheximide (10 mg/ml) and, where
indicated, with EGF for the times indicated above each lane. Cells were lysed and equivalent amounts of each sample (40 mg of protein) were
analysed using western blotting with antibodies against BST-2, HRS, EGF-Receptor and tubulin as a loading control. For each sample, BST-2 signal
intensity was quantified using the ‘‘Multi Gauge’’ software and used to calculate the relative amount of BST-2 at each time point. Values at time 0
were set to 100% in the graph shown on the right. The data presented are representative of 3 independent experiments. (B) Analysis of BST-2
turnover upon TSG101 depletion. HeLa cells transfected with either control siRNA (CT) or siRNA targeting TSG101 were treated 3 days after
transfection as described above (A). The data presented are representative of 2 independent experiments (see also Figure S5). (C) Effect of
overexpression of HRS and dominant negative VPS4 mutant on BST-2 distribution. HeLa cells transfected with plasmids encoding GFP,
GFP-HRS, GFP-VPS4, or GFP-VPS4-E/Q for 16 hrs and permeabilized before fixation and staining with mouse polyclonal anti-BST-2. Colocalisation was
assessed by confocal microscopy. Bar: 10 mm.
doi:10.1371/journal.ppat.1001265.g004
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PLoS Pathogens | www.plospathogens.org 9 February 2011 | Volume 7 | Issue 2 | e1001265Figure 5. Impact of HRS depletion on the release of Vpu defective HIV-1 particles. HeLa cells were transfected with either control siRNA
(CT) or siRNA targeting HRS and infected with either VSV-G pseudotyped wt NL4-3 HIV-1 (NL4-3 WT) viruses or VSV-G pseudotyped Vpu-defective
NL4-3 (NL4-3 Udel) viruses. (A) Western-blot analysis of infected siRNA-treated cells (upper panels) and pelleted virus (lower panel). (B) CAp24 present
within the cells (Cell-associated CAp24, dark-grey graph bars) and released in the supernatant of the infected cells (Released CAp24, light-grey graph
bars) was measured by ELISA. The values were normalized to those obtained for control cells (CT) infected with WT viruses set to 100%.
Quantifications were performed in duplicate. Bars represent the mean 2/+ SD from 3 independent experiments.
doi:10.1371/journal.ppat.1001265.g005
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PLoS Pathogens | www.plospathogens.org 10 February 2011 | Volume 7 | Issue 2 | e1001265Figure 6. Effect of HRS depletion on the release of HIV-1 particles from non-restrictive HEK 293T cells. HeLa cells and HEK 293T cells
transfected with either control siRNA (CT) or siRNA targeting HRS were infected with VSV-G-pseudotyped NL4-3 HIV-1 (NL4-3 WT). (A) Western-blot
analysis of infected siRNA-treated cells (Upper panels) and viral particles released in the supernatant (Lower panel). Tubulin is the loading control. (B,
C) CAp24 present within the cells (Cell-associated CAp24, dark grey graph bars) and released from the infected cells (Released CAp24, light-grey
graph bars) was measured by ELISA quantification. The experiment was performed in duplicate. For each cell type, values obtained for HRS depleted
cells were normalized to those obtained for the control cells (set as 100%). Bars represent the mean 2/+ SD from 3 independent experiments.
doi:10.1371/journal.ppat.1001265.g006
HRS and BST-2/Tetherin Down-Regulation
PLoS Pathogens | www.plospathogens.org 11 February 2011 | Volume 7 | Issue 2 | e1001265Figure 7. HRS depletion does not alter the release of HIV-1 particles in HeLa cells depleted for BST-2. HeLa cells transfected with either
control siRNA (CT) (lanes 1 and 5) or siRNA targeting HRS (lanes 2 and 6), BST-2 (lanes 3 and 7) or both HRS and BST-2 (lanes 4 and 8). The cells were
then infected with either VSV-G pseudotyped wt NL4-3 HIV-1 (NL4-3 WT) or VSV-G pseudotyped Vpu-defective NL4-3 (NL4-3 Udel) viruses at a MOI of
0.5. (A) Western-blot analysis of infected siRNA-treated cells (Upper panels) and viral particles released in the supernatant (Lower panel). Tubulin is
the loading control. (B) CAp24 present within the cells (Cell-associated CAp24, dark grey graph bars) and released from the infected cells (Released
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PLoS Pathogens | www.plospathogens.org 12 February 2011 | Volume 7 | Issue 2 | e1001265HRS in HIV-1 morphogenesis was previously investigated in
HEK 293T cells. In that study, over-expression of HRS or HRS
deletion mutants induced a ‘‘late budding phenotype’’ by depleting
the pool of free TSG101 available to Gag to promote viral scission
[23]. These data are not incompatible with our current results, but
use of RNA interference and BST-2 expressing cells (HEK 293T
cells do not constitutively express BST-2/tetherin and are non-
restrictive for Vpu-defective HIV-1) allowed us to uncover an
additional level of ESCRT-mediated regulation of HIV-1 release.
A key finding suggesting that HRS might influence virus release
was the observation of large clusters of mature virus particles on
the surface and in endosomes of HIV-1 infected HRS depleted
cells (Figure 3). This phenotype was reminiscent of that observed
following infection of BST-2-expressing cells with Vpu-defective
HIV-1 [13] and was clearly different from that induced by the
absence of TSG101 recruitment to budding sites, which is
characterized by the cell surface accumulation of incomplete
immature viral buds [5]. This suggested that HRS might
contribute to the mechanism counteracting BST-2 restriction of
HIV-1 release.
We therefore investigated whether the ESCRT machinery, and
in particular HRS and TSG101, facilitate BST-2 down-modula-
tion and degradation. Previous studies have indicated that BST-2
undergoes clathrin-mediated endocytosis from the plasma mem-
brane and traffics through recycling endosomes and the trans Golgi
network (TGN) [24]. Indeed a significant fraction of BST-2 is
located in the TGN at steady state [25,26]. Here we show that
BST-2 undergoes rapid constitutive turnover in HeLa cells (half
time , 2 h) that is dependent on both HRS and TSG101,
suggesting that although BST-2 cycles between the plasma
membrane, endosomes and the TGN, a significant fraction is
sorted to lysosomes and degraded. Interference with the ESCRT
machinery, and associated effects on lysosomal sorting and
degradation, by RNA interference or over-expression of WT or
dominant negative proteins of the MVB pathway, resulted in
inhibition of constitutive BST-2 degradation and its accumulation
in intracellular structures that are likely to be endosomes and/or
the TGN (Figure 4 and Figure S5). Thus, the ESCRT machinery,
and in particular HRS and TSG101, sorts BST-2 to the ESCRT/
MVB degradation pathway and Vpu appears to enhance this
degradation, leading to barely detectable levels of BST-2 in HIV-1
infected cells (Figure 8).
Vpu abrogation of the restriction to HIV-1 release is associated
with BST-2 down-regulation from the surface of infected cells
[11,12,15,17,22]. To date, the exact mechanism through which
Vpu reduces BST-2 expression is not clearly understood. Vpu may
decrease BST-2 cell surface expression by increasing its endocy-
tosis and/or by decreasing its recycling to the cell surface, thereby
diverting more of the internalized protein to lysosomes. Recent
studies reported that Vpu does not increase the rate of BST-2
endocytosis [17] and that BST-2 mutated on two cytosolic domain
tyrosine residues (Y6/Y8) involved in its internalization remains
sensitive to Vpu [27,28,29]. However, inhibition of endocytosis by
the dynamin 2-K44A mutant, as well as depletion of the clathrin
adaptor AP2, partially impair Vpu-induced BST-2 down-regula-
tion from the plasma membrane [17,29]. In addition, Vpu
accelerates the internalization rate of the BST-2 Y6/Y8 mutant
[30], suggesting a role for Vpu in BST-2 endocytosis. Alterna-
tively, other studies suggest that Vpu may slow the transport of
BST-2 (both newly synthesized and recycled) to the cell surface
and sequester the restriction factor in a perinuclear compartment
[27,31,32]. This last model is reminiscent of the mechanism by
which the Env proteins from HIV-2 and tantalus monkey SIV
(SIVtan) overcome BST-2 restriction, whereby BST-2 is redistrib-
uted from the cell surface to intracellular compartments, such as
recycling endosomes and/or the TGN, without degradation
[33,34,35]. Finally, it has been proposed that Vpu enhances the
release of HIV-1 in the absence of BST-2 cell surface down-
regulation and intracellular depletion [21,36], suggesting another
mechanism of Vpu action on BST-2 restriction.
Our data indicate that the integrity of the ESCRT/MVB
pathway is required for Vpu to counteract BST-2 restriction. HRS
depletion reduces Vpu-induced cell surface down-regulation of
BST-2, impairs Vpu-induced BST-2 degradation and reduces
HIV-1 release (Figures 1, 8 and S4). Moreover, expression of
dominant negative mutant of the AAA-ATPase VPS4 (VPS4-
E223Q), another component of the ESCRT machinery, impairs
Vpu-induced cell surface down–regulation of BST-2 (Figure 9).
Together with observations that inhibitors of the endosomal/
lysosomal pathway impair Vpu-induced BST-2 down-regulation
[17,22], our data support a model in which Vpu may sort BST-2
at the level of endosomes, reducing its recycling to the plasma
membrane [17,22]. This model is also in agreement with the
redistribution of BST-2 to transferrin receptor positive endosomal
compartments upon HIV-1 infection, as described by Habermann
et al. [37]. Accordingly, one could postulate that the accumulation
of BST-2 in HRS depleted cells exceeds the degradation capacity
of Vpu and inhibits the release of wild-type HIV-1 by misrouting
BST-2 back to the cell surface.
Vpu downregulates the cell surface expression of BST-2 and
increases its degradation [11,12,15,17,22]. Whether Vpu targets
BST-2 for proteasomal or lysosomal degradation is still a matter of
debate. Experiments using proteasome inhibitors or a dominant
negative mutant of ubiquitin have suggested that Vpu connects
BST-2 to the Skp1-cullin-F-Box (SCF) ubiquitin ligase complex
and targets it for proteasomal degradation, as described for Vpu-
mediated degradation of CD4 [11,12,38]. However, prolonged
treatment with proteasome inhibitors can deplete cellular pools of
free ubiquitin and thereby indirectly affect alternative ubiquitin-
dependent sorting and degradation pathways [18]. Studies using
inhibitors of the endosomal/lysosomal pathway support a model in
which Vpu targets BST-2 for lysosomal degradation [17,22].
Although our data cannot rule out the involvement of the
proteasome pathway, the involvement of HRS and the ESCRT
machinery in both constitutive and Vpu-enhanced degradation of
BST-2 strongly supports a role for lysosomal degradation in BST-2
down regulation. How Vpu targets BST-2 to the MVB pathway is
also unclear. Studies have reported that Vpu interacts with BST-2
through the transmembrane domains of both proteins [27,29] and
endosomal co-localisation of BST-2 with Vpu has been described
[13,15]. Interestingly, we showed that HRS interacts with BST-2
and Vpu (Figure 10). One model to explain these observations is
that through binding with BST-2 [27,29] and HRS, Vpu might
stabilize BST-2 on endosomal membranes and, by recruiting the
b-TRCP2-Skp1-cullin E3 ubiquitin ligase complex, allow the
efficient ubiquitination of BST-2 to permit its recognition by the
ESCRT machinery through HRS, as discussed in a recent study
[17]. Indeed, recent studies have shown that b-TRCP2, a
subunit of the Skp1-cullin1-F-Box (SCF) ubiquitin ligase com-
plex is required for Vpu to down-regulate BST-2 expression
CAp24, light-grey graph bars) was measured by ELISA. The values were normalized to those obtained for control cells (CT) infected with WT viruses
set to 100%. Bars represent the mean -/+ SD from 3 independent experiments.
doi:10.1371/journal.ppat.1001265.g007
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PLoS Pathogens | www.plospathogens.org 13 February 2011 | Volume 7 | Issue 2 | e1001265Figure 8. HRS is required for Vpu-induced BST-2 degradation and cell surface down-regulation. (A–B) HRS depletion prevents Vpu
from targeting BST-2 for degradation. (A) HeLa cells transfected with either control siRNA (CT) or siRNA targeting HRS were infected with either
VSV-G pseudotyped wt NL4-3 HIV-1 (NL4-3 WT) or VSV-G pseudotyped Vpu-defective NL4-3 (NL4-3 Udel) viruses at a MOI of 1, or left non-infected
(NI). Forty-eight hours after infection, some of the cells were incubated with cycloheximide for 4 h and lysed. Cell lysates were analysed by western-
blot. Tubulin is the loading control. These data are representative of 2 independent experiments. (B) HeLa cells transfected with either control siRNA
(CT) or siRNA targeting HRS were infected with VSV-G pseudotyped NL4-3 HIV-1 (NL4-3 WT) and processed for immunolabelling with mouse
polyclonal BST-2 and human HIV-1 Env (2G12) antibodies. Cells were imaged by confocal microscopy. Env staining discriminates between infected
cells (arrows) and non-infected cells (arrowheads). Bar: 10 mm. (C–D) HRS depletion impairs Vpu-induced cell surface down regulation of
BST-2. HeLa cells transfected with either control siRNA (CT) or siRNA targeting HRS were infected with VSV-G pseudotyped NL4-3 HIV-1 at a MOI of
0.5. Forty-eight hours later the cells were stained with rabbit polyclonal antibody against BST-2 (BST-2; upper panels) or rabbit polyclonal IgGs as an
isotype control (CT IgG; lower panels), followed by a staining with a Cy5-conjugated donkey anti-rabbit antibody. The cells were then fixed,
permeabilized and stained for Gag using a FITC-conjugated mouse monoclonal anti-CAp24. The cells were then processed for flow cytometry
analysis. (C) Dot plot. Vertical lines indicate the gates set using non-infected cells stained as indicated. Gate B1 represents non infected cells and gate
B2: infected-cells. (D) Bar graph representation of cell surface level of BST-2 in CAp24 negative cells (black bars) and CAp24 positive cells (grey bars)
for each siRNA condition. Values are expressed as the Mean Fluorescence Intensity (MFI) on gate B1 (black bars) and B2 (grey bars) respectively. Error
bars represent the –/+ SD from 3 independent experiments.
doi:10.1371/journal.ppat.1001265.g008
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recruited to endocytic membranes [39]. Moreover, it has been
described that certain receptors, such as the growth hormone
receptor (GHR) and the interferon a receptor (IFNAR1), are
targeted for lysosomal degradation following their binding to b-
TRCP2 and subsequent ubiquitination [40,41].
Physiologically, HRS is involved in the recognition of
ubiquitinylated protein flagged for lysosomal degradation. BST-2
was recently shown to be ubiquitinylated and Vpu expression was
shown to increase this ubiquitination [42,43]. BST-2 contains two
lysine residues, the common target of ubiquitination, in its
cytosolic N-terminal domain at positions 18 and 21. Mutation of
these residues does not impair BST-2 sensitivity to Vpu-mediated
down-regulation, suggesting that BST-2 ubiquitination is not
required for Vpu to target BST-2 to the MVB degradation
pathway [12,28,42]. However, residues other than lysine may
undergo ubiquitination (e.g. cysteine, threonine and serine
residues). Ubiquitination of lysine and serine/threonine residues
in the cytosolic domain of CD4 has been shown to be required for
its targeting to the degradation pathway by Vpu [44]. BST-2
contains a threonine and two serine residues at positions 3 to 5
and, interestingly, ubiquitination of BST-2 on these residues was
recently shown to be involved in Vpu-induced release of viral
particles [43]. These observations together with indirect evidence
from the use of drugs that affect cellular ubiquitin pools, suggest a
role for ubiquitin in Vpu-induced targeting of BST-2 to the
degradation pathway [11,12,17,43]. Further analyses will be
necessary to decipher the exact role of HRS in targeting BST-2
to the MVB pathway under physiological conditions and after
infection by HIV-1, and the requirement for ubiquitination in
these processes. Moreover, it would be interesting to further
establish the role of this pathway in Vpu’s function in the natural
Figure 9. Overexpression of a dominant negative VPS4 mutant impairs Vpu-induced BST-2 cell surface down-regulation. (A) HeLa
cells were transfected with plasmids encoding GFP-VPS4 or GFP-VPS4-E223/Q along with plasmids encoding the provirus NL4-3 wt (red and purple
histograms) or Vpu-defective NL4-3 (NL4-3 Udel; blue and black histograms). Forty-eight hours later, the cells were co-stained with a mouse
monoclonal antibody against BST-2 (BST-2; upper panels) or isotype control mouse IgG1 (CT Isotype; lower panels) and a human monoclonal
antibody against Env. Cells were then co-stained with Alexa 647-conjugated donkey anti-mouse and PE-conjugated donkey anti-human antibodies,
fixed, and processed for flow cytometry analysis. Histograms represent the relative cell number vs. BST-2 or Isotype IgG fluorescence intensity for the
GFP HIV-1 positive cells (GFP + PE positive cells). Dotted histograms are the isotype controls. This experiment is representative of 3 independent
experiments. (B) Bar graph representation of cell surface BST-2 in cell expressing (i) GFP-VPS4 wt along with HIV-1 NL4-3 WT (red bar) or HIV-1 NL4-3
Udel (blue bar) or (ii) GFP-VPS4-E223/Q CAp24 along with HIV-1 NL4-3 WT (purple bar) or HIV-1 NL4-3 Udel (black bar). Values are expressed as the
Mean Fluorescence Intensity (MFI) obtained for BST-2 staining minus MFI values obtained for the corresponding isotype control. Error bars represent
the –/+ SD from 3 independent experiments.
doi:10.1371/journal.ppat.1001265.g009
Figure 10. HRS interacts with BST-2 and Vpu. HEK 293T cells were transfected with empty plasmid encoding SBP-CBP (pNTAP-) along with
plasmid encoding Flag-tagged BST-2 (Flag-BST-2) and HA-tagged Vpu (HA-Vpu, Lanes 1 and 5) or expression vector for SBP-CBP-tagged HRS (pNTAP-
HRS) along with Flag-BST-2 (Lanes 2 and 6); HA-Vpu (Lanes 3 and 7) or both proteins (Lanes 4 and 8). The relative amounts of plasmids transfected
were kept constant by adding the corresponding empty vector. Twenty-four hours later the cells were lysed and SBP-CBP-HRS was pulled-down and
binding of HA-Vpu and Flag-BST-2 was analysed by western-blot. Left panels represent the input and right panels represent bound proteins. The data
is representative of 4 independent experiments.
doi:10.1371/journal.ppat.1001265.g010
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macrophages.
In summary, we show that HRS facilitates the constitutive
turnover of BST-2/tetherin and that Vpu enhances this
degradation. HRS is required for Vpu to efficiently down-regulate
BST-2 from the surface of the cells and to target BST-2 to the
MVB/lysosomal degradation pathway, thereby promoting HIV-1
release. This highlights a role for HRS and the ESCRT/MVB
pathway in the regulation of Vpu function. Although the precise
molecular and cellular mechanisms by which Vpu connects to the
ESCRT machinery to modulate BST-2 expression remains to be
elucidated, our data bring significant new insights to understand-
ing how this viral protein uses cellular machineries to counteract
host cell restriction and favour HIV-1 dissemination.
Materials and Methods
Recombinant DNA procedures
HRS and VPS4 cDNA were cloned into pEGFP-C vector
(Clontech, France). The VPS4 E223Q mutant was made by PCR
mutagenesis using the QuikChange II site directed mutagenesis kit
(Stratagene, France). Expression vectors for HRS fused to the
Streptavidin binding protein (SBP) and Calmodulin binding
protein (CBP) affinity tags were obtained by cloning HRS into
the pNTAP-B vector (Stratagene, France). The expression vector
for Flag-tagged BST-2 was obtained by cloning of BST-2 into
p3XFlag vector. cDNA for HA tagged-Vpu cloned into
pCDNA3.1 was a gift from Dr. Florence Margottin-Goguet [45]
All mutagenesis and subclonings were verified by DNA sequenc-
ing.
Cell culture and transfection
HeLa, HeLa P4R5 MAGI (NIH; NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID), HeLa
TZM-bl (NIH) and HEK 293T cells were grown in DMEM plus
glutamine, antibiotics and 10% decomplemented-FCS (foetal calf
serum) (GibcoBRL, Invitrogen). HeLa P4R5 MAGI cell cultures
were supplemented with 100 mg/mL geneticin and 1 mg/mL
puromycin.
The 21-nucleotide RNA duplexes designed to target HRS (59
CGACAAGAACCCACACGUCdTdT 39 at positions 162-180)
or TSG101 (59 CCUCCAGUCUUCUCUCGUCdTdT 39 at
positions 415-433) were previously described [5,16] and synthe-
sized by Thermo Scientific Dharmacon (Perbio Science, France).
The On-target plus SMART-pool siRNA targeting BST-2 was
purchased from Dharmacon (# L-011817-00). The On-target plus
non-targeting siRNA 1 (# D-001810-01 from Dharmacon) was
used as control. The cells were transfected with 4 to 30 nM siRNA
using Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions.
Transient transfections of HeLa and HEK 293T cells with
mammalian expression vectors were performed using FuGENE
(Roche diagnostics) following the manufacturer’s instructions.
Cycloheximide treatment
Cells were pre-incubated for 45 min with DMEM plus 10 mM
Hepes, 1 mg/ml BSA (Calbiochem, VWR) and 10 mg/ml
Cycloheximide (Calbiochem). The cells were then washed and
incubated for the indicated times in regular growth medium plus
10 mM Hepes, 10 mg/ml cycloheximide and 150 ng/ml Epider-
mal Growth Factor (EGF) (Invitrogen) where indicated. The cells
were harvested, washed in PBS, lysed and analysed by western
blotting as described [46].
Viral stocks
Stocks of HIV-1 NL4-3 WT (NIH), HIV-1 NL4-3 Udel [47],
VSV-G pseudotyped NL4-3 WT and VSV-G pseudotyped NL4-3
Udel were obtained as described [46]. Viral titres (Multiplicity of
Infection: MOI) were assessed by infection of the indicator cells
HeLa TZM-bl (bearing the b-galactosidase gene under the control
of HIV-1 LTR) with serial dilutions of the stocks, followed by a b-
galactosidase coloration of the cells and counting of blue cells.
HIV-1 replication assay
HeLa P4R5 cells (1610
5) transfected with siRNA were infected
with NL4-3 HIV-1 at an MOI of 0.005. Six hours after infection,
cells were washed and placed in fresh medium. Supernatants were
collected every 24 h for 4 days and used for HIV-1 CAp24
quantification by ELISA. At the end of the experiment, cells were
lysed and HRS depletion was assessed by western blotting using
rabbit anti-HRS (Euromedex, France) and mouse anti-tubulin
(DM1A, Sigma, France) antibodies.
HIV-1 production, infectivity and incorporation assays
For HIV-1 production assays on a single round of replication,
HeLa cells or 293T cells were treated with siRNA as described
above. After 48 h, cells were infected with NL4-3 (WT or Udel)
HIV-1 pseudotyped with VSV-G for 6 hours at an MOI of 0.5.
The cells were washed 24 h later, and incubated for a further
24 h. Supernatants were then collected, 0.45 mm-filtered, and used
for HIV-1 CAp24 quantification by ELISA (released CAp24).
Viral particles released into the supernatant were pelleted through
a 20% sucrose cushion by ultracentrifugation at 150 000 g for
90 min, and resuspended in Laemmli buffer. Pelleted viruses were
analysed by western blotting using mouse anti-CAp24 (ARP366,
NIBSC). The cell lysates were analyzed by western blotting using
mouse anti-CAp24 (ARP366, National Institute for Biological
Standards and Control (NIBSC), UK), mouse anti-MAp17 (18A,
Hybridolab, France), mouse anti-SUgp120 (110H, Hybridolab),
human anti-TMgp41 (2F5, NIH), rabbit anti-Vpu (NIH), rabbit
anti-Nef (NIH), rabbit anti-HRS (Euromedex France, Souffel-
weyersheim, France), mouse anti-TSG101 (BD-Biosciences,
France), rabbit anti-BST-2 (NIH) and mouse anti-tubulin
antibodies. HIV-1 CAp24 antigen contained in the cell lysates
(cell-associated CAp24) was also quantified by ELISA.
In a single round infectivity assay, the titres of released viruses
were determined by infection of the indicator cells HeLa TZM-bl
in a standardized 96-well titration assay by luminometric analysis
of firefly luciferase activity (Kit luciferase Assay reagent, Promega,
France) following the manufacturer’s instructions.
GST-pull down experiments
The GST-pull down experiment was done using cytosolic
extracts of siRNA transfected HeLa cells prepared in 50 mM Tris
pH 7.6, 150 mM NaCl, 2 mM EDTA, 0.5% (v/v) Triton X-100
(lysis buffer). Aliquots (2 mg) of purified GST, GST-p6 or GST-
Gag proteins were immobilized on glutathione-Sepharose beads
(GE healthcare) and incubated for 4 h with 2 mg of cell extract
(diluted in 500 ml of lysis buffer). The beads were then washed 3
times in lysis buffer and once in PBS, and bound cellular proteins
were separated by SDS-PAGE and revealed by western blotting
using antibodies to TSG101, HRS and tubulin.
Tap-Tag experiments
HEK 293T cells were transfected with (a SBP-CBP-tagged HRS
expression vector (pNTAP-HRS) or the corresponding empty
vector (pNTAP) along with HA-tagged Vpu and Flag-tagged BST-
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vector along with HA-tagged Vpu and p3X-Flag empty vector or
(c) Flag-tagged BST-2 expression vector and PCDNA3-1 empty
vector. Cells were harvested 24 hours after transfection and lysed
following instructions provided by the Interplay mammalian TAP-
system (Stratagene, France). The cell lysates were cleared by
centrifugation and subjected to two consecutive rounds of pull-
down by incubation with a Streptavidin resin, followed by the
elution of the bound cellular proteins and incubation of the eluted
protein with a Calmodulin resin (following the manufacturer’s
instructions). The beads were then washed in lysis buffer and the
TAP-purified proteins were resolved by SDS-PAGE and revealed
by western blotting using antibodies to HRS, HA and Flag.
Flow cytometry
Forty eight hours post-infection, siRNA transfected HeLa cells
were harvested by scrapping, washed twice in cold PBS/1% (w/v)
BSA and stained for 1 hour at 4uC with rabbit anti-BST-2
antibody (NIH) or control rabbit IgGs (rabbit serum; Sigma,
France) in PBS/1%BSA. The cells were then washed three times
in PBS/1%BSA, and stained for 1 hour at 4uC with a cy5-
conjugated donkey anti-rabbit antibody in PBS/1%BSA. Cells
were washed, fixed in 4% paraformaldehyde (PFA), quenched for
10 min in PBS/0.1 M glycine, and then permeabilized in PBS/
1% BSA/0.05% saponin before staining with a FITC-conjugated
anti-CAp24 (KC57-FITC, Beckman Coulter, France). Cells were
washed and fixed in PBS/1% BSA/1% PFA before analysis using
the Cytomics FC500 Flow Cytometer (Beckman Coulter). Gates
for FITC were set using non-infected cells.
HeLa cells transfected with plasmids encoding the GFP-tagged
constructs along with plasmid encoding the provirus NL4-3 wt or
Vpu-defective NL4-3 (NL4-3 Udel) were harvested 48 hours after
transfection and stained for 1 hour at 4uC with anti-BST-2 mouse
monoclonal antibody (Abnova, Tebu-bio; France) or isotype
control mouse IgG1 (BD-bioscience; France), along with human
anti-Env antibody (2G12, NIBSC), in PBS/1%BSA. The cells
were then washed three times in PBS/1% BSA, and stained for
1 hour at 4uC with an Alexa 647-conjugated donkey anti-mouse
and PE-conjugated donkey anti-human antibodies in PBS/1%
BSA. Cells were washed, fixed in PBS/1% BSA/1% PFA before
analysis using the Cytomics FC500 Flow Cytometer. Gates for
GFP and PE were set using respectively non-transfected and non-
infected cells. All the data were analysed using the CXP cytometer
software.
Immunofluorescence microscopy
Cells, grown on cover slips, were permeabilized in PBS/0.1%
BSA/0.05% saponin [16] before fixation with 4% PFA in PBS for
15 min. PFA-fixed cells were permeabilized and blocked with
0.2% BSA/0.1% saponin in PBS for 30 min. Cells were incubated
for 30 min with mouse anti-BST-2 antibody (Abnova, France)
alone or together with human anti-Env antibody (2G12, NIH) in
blocking solution, washed and incubated for 30 min with
appropriate fluorophore-conjugated secondary antibodies. Cells
were analyzed with a Leica SP2 confocal microscope. Series of
optical sections were recorded and image processing was
performed using Adobe Photoshop CS2 software.
Labeling of cryosections for immunofluorescence or EM
Cells were fixed in 4% PFA in 0.1 M sodium phosphate buffer,
pH 7.4, embedded in gelatine, and frozen for cryosectioning, as
described previously [48,49]. For immunofluorescence staining,
semi-thin (0.5 mm) cryosections were placed on glass slides,
quenched in 50 mM glycine/50 mM NH4Cl and extracted for
6 min in 0.1% Triton X-100. Sections were stained with
antibodies to MAp17 (4C9, ARP 342, NIBSC) and Env (2G12,
NIBSC) and goat anti-mouse Alexafluor-488 and goat anti-
human-Alexafluor-594 (Invitrogen) diluted in PBS/1% BSA, and
mounted in Mowiol. Sections were examined with an Axioskop
(Carl Zeiss MicroImaging, Inc.); images were recorded with a
CCD camera (Orca C4742-95; Hamamatsu) and processed using
Adobe Photoshop 8.
For immuno-EM, ultrathin cryosections (50 nm) were stained
with mouse antibodies against HIV-1 p24/p55 (ARP365 and
ARP366, NIBSC), a rabbit anti-mouse bridging antibody
(DakoCytomation, Ely, UK), and 5 nm PAG (Protein A gold
reagents were obtained from the EM Lab, Utrecht University,
Utrecht, The Netherlands). Sections were fixed in 1% (v/v)
glutaraldehyde for 10 min, quenched in 50 mM glycine-50 mM
NH4Cl in PBS and incubated with the human anti-Env mAb
2G12 and 10 nm PAG. Sections were embedded in uranyl acetate
in methylcellulose, as described previously [49], and examined
with a Technai G2 Spirit transmission electron microscope (FEI
Company UK. Ltd., Cambridge, UK). Digital images were
recorded with a Morada 11 MegaPixel TEM camera (Soft
Imaging System) and the AnalySIS software package. Images were
adjusted for brightness and contrast, and figures were assembled
with Photoshop 8.
Supporting Information
Figure S1 HRS depletion does not affect entry of HIV-1 in
HeLa P4R5 cells. HeLa P4R5 cells, transfected with either control
siRNA (CT) or siRNA targeting HRS, were infected with NL4-3
HIV-1 WT at a low MOI=0.001. Cells were washed 4 h later
and placed in fresh medium supplemented with AMD3100, a
CXCR4 inhibitor. After 24 h, the cells were fixed with 0.5%
glutaraldehyde in PBS and infected cells revealed by X-gal
coloration (potassium ferrocyanide hydrate 4 mM, potassium
ferricyanide 4 mM, MgCl2 2 mM, X-Gal (5-bromo-4-chloro-3-
indolyl b-D-galactopyranoside) 0.4 mg/ml). Blue coloured cells
were counted in duplicate and values were normalized to those
obtained for the control cells (set as 100%). Bars represent the
mean 2/+ SD from 3 independent experiments. CT/NI
corresponds to non-transfected, non-infected cells.
Found at: doi:10.1371/journal.ppat.1001265.s001 (0.17 MB TIF)
Figure S2 Binding of TSG101 to Gag. Lysates of HeLa cells
transfected with either control siRNA (CT) or siRNA targeting
HRS or TSG101 were incubated with equal amounts of purified
GST (lanes 4 to 6) or GST-Gag (lanes 8 to 10). TSG101 binding
and HRS depletion were analysed by western blotting (upper
panels). Tubulin is the loading control for cellular proteins. Lower
panel: Ponceau red staining of the membrane used for western
blotting. These data are representative of 3 independent
experiments.
Found at: doi:10.1371/journal.ppat.1001265.s002 (0.46 MB TIF)
Figure S3 HRS depletion decreases Env incorporation in
nascent viral particles. HeLa cells transfected with either control
siRNA (CT) or siRNA targeting HRS, were infected with VSV-G
pseudotyped wt NL4-3 HIV-1 (NL4-3 WT). Supernatants of
infected cells were harvested 48 h later, 0.45 mm-filtered, and the
virions pelleted through a 20% sucrose cushion by ultracentrifu-
gation at 150 000 g for 90 min. The virus pellets were
resuspended in Laemmli buffer. Cell lysates and pelleted viruses
were analysed by western blotting using mouse anti-CAp24
(ARP366, NIBSC), mouse anti-TMgp41 (41A, Hybridolab) and
anti-tubulin antibodies. Left panels represent loading of equal
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of viral proteins in HRS depleted cells). Middle panels represent
loading of equal volumes of the virus samples (to visualize the
decrease of virus release in HRS depleted cells). Left panels
represent loading of equal amounts of viral particles (equal amount
of CAp24; to visualize Env content for a fixed amount of viral
particles).
Found at: doi:10.1371/journal.ppat.1001265.s003 (0.34 MB TIF)
Figure S4 Further immuno-EM images of control HeLa cells or
cells treated with siRNA for Hrs. HeLa cells were transfected with
either siRNA control (A, B) or siRNA targeting HRS (C - F). After
48 h, the cells were infected with NL4-3 HIV-1 pseudotyped with
VSV-G and, after a further 48 h, fixed and prepared for
cryosectioning. Ultrathin (50 nm) cryosections were double
labelled with antibodies against Gag p24/p55 (5 nm PAG) and
anti-Env 2G12 (10 nm PAG). Infected cells were identified by the
scattered 5 nm gold particles (Gag p55) over the cytoplasm (e.g. as
indicated by the arrows). The Env protein (10 nm PAG, e.g. at the
arrowheads) was seen over membranes near the Golgi apparatus
(referred as G, see panels A and C). In control siRNA-treated cells,
some mature virus particles labelled with both 5 nm and 10 nm
PAG particles are seen at the cell surface (B). In cells treated with
HRS siRNA, the extracellular virus clusters were more prominent
(D, E), and virus particles were also seen in intracellular vacuoles
resembling endosomes (En, see panel F). Mv identifies microvillar
protrusions, while PM marks the plasma membrane. Scale bars
=200 nm.
Found at: doi:10.1371/journal.ppat.1001265.s004 (9.91 MB TIF)
Figure S5 Analysis of BST-2 expression in HRS and TSG101
depleted cells. (A) Western blot analysis of BST-2 expression in
HRS depleted cells: HeLa cells were transfected with control
siRNA (CT) or siRNA targeting HRS. Four days after
transfection, cells were lysed and equivalent amounts of each
sample were analysed by western blotting using antibodies against
BST-2, HRS and tubulin as a loading control. (B) Western blot
analysis of BST-2 expression in TSG101 depleted cells: HeLa cells
were transfected with either control siRNA (CT) or siRNA
targeting TSG101. Three days after transfection, cells were lysed
and equivalent amounts of each sample were analysed by western
blotting using antibodies against BST-2, TSG101 and tubulin as a
loading control. (C) Immunofluorescence analysis of BST-2
expression in HRS and TSG101 depleted cells: HeLa cells were
transfected with either control siRNA (CT) or siRNA targeting
HRS or TSG101. Cells were permeabilized before fixation and
then stained with mouse polyclonal antibody against BST-2 and
rabbit polyclonal antibody against HRS, followed by staining with
Alexa488 conjugated anti-mouse IgG or Alexa594 conjugated
anti-rabbit IgG, respectively. Cells were imaged by confocal laser
scanning microscopy. Bar: 10 mm.
Found at: doi:10.1371/journal.ppat.1001265.s005 (1.15 MB TIF)
Table S1 HRS depletion impairs Vpu-induced cell surface down
regulation of BST-2. Hela cells transfected with control siRNA
(CT) or a siRNA targeting HRS were infected with VSV-G
pseudotyped NL4-3 HIV-1. Forty eight hours later the cells were
stained for cell surface BST2 followed by an intracellular staining
of the Gag product CAp24. Data represent the level of cell surface
expression of BST2 (expressed in MFI) in CAp24 negative cells
(gate B1) vs. CAp24 positive cells (gate B2) from 3 independent
experiments. These data were used to draw the bar graph in
Figure 8D.
Found at: doi:10.1371/journal.ppat.1001265.s006 (0.20 MB TIF)
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